Intravenous Immunoglobulin
Intravenous Immunoglobulin - Related Videos
07:22
Discontinuing Intravenous Fluids and a Peripheral Intravenous Line
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT Intravenous (IV) fluid administration and peripheral IV catheters (PIVs) may be discontinued for a number of reasons. The most common reason for discontinuing IV fluids is that the patient has returned to normal body fluid volume (euvolemia) and is able to maintain adequate oral fluid intake or is being discharged from the hospital. In addition, the Centers for Disease Control Guidelines...
04:48
A Paper-Based Immunoassay for the Detection of Immunoglobulin G
0 Views •
2025
The video demonstrates a paper-based immunoassay, involving amine-functionalized cellulose discs cross-linked with glutaraldehyde. Covalent immobilization of IgG-Fc-specific capture antibodies, followed by the introduction of immunoglobulin G and horseradish peroxidase-conjugated detection antibodies, results in a color change confirming the presence of immunoglobulin G.
03:31
A Microfluidic Cartridge-Based Detection System for Allergen-Specific Immunoglobulin E
0 Views •
2025
This video demonstrates a protocol for detecting serum-specific immunoglobulin E using a microfluidic cartridge-based chemiluminescence system. Serum IgEs interact with distinct allergens immobilized in the reaction zone of the cartridge, which are subsequently detected with peroxidase-conjugated anti-IgE antibodies and a chemiluminescent substrate, allowing simultaneous detection of multiple allergen-specific IgEs.
04:51
Measuring Immunoglobulin G Levels Against a Test Vaccine in a Mouse Serum
0 Views •
2025
This video demonstrates a method for assessing the antibody immune response to a novel nanoemulsion adjuvant vaccine in pre-immunized mice. Immunization enhances antibody response as confirmed by determining the IgG antibody titers.
11:39
Peripheral Intravenous Catheter Insertion
0 Views •
2023
Source: Madeline Lassche, MSNEd, RN and Katie Baraki, MSN, RN, College of Nursing, University of Utah, UT The purpose of peripheral intravenous catheter (PIV) insertion is to infuse medications, perform intravenous (IV) fluid therapy, or inject radioactive tracers for special examination procedures. Placing a PIV is an invasive procedure and requires the use of an aseptic, no-touch technique. Common IV venipuncture sites are the arms and hands in adults and the feet in children. According to...
FAQs
Fc-mediated interactions allow pooled IgG to influence immune cells through Fc receptors, which are antibody-binding structures on cell surfaces. By altering signaling through these receptors, IVIG can regulate immune activity rather than simply provide pathogen-binding antibodies. This mechanism is especially relevant when abnormal immune activation contributes to autoimmune or inflammatory disease.
IVIG can act directly through antibody binding that neutralizes pathogens, while also modulating complement, a protein system that participates in immune defense and inflammation. These mechanisms address different parts of the immune response: neutralization limits pathogen activity, whereas complement modulation can alter downstream inflammatory effects. Their relative importance depends on the disease mechanism.
Responses to IVIG vary because the preparation contains pooled antibodies whose composition can influence which targets are recognized and how immune pathways are engaged. Dose also affects the amount of antibody available, while the underlying disease mechanism determines which actions are relevant. Consequently, the same treatment may produce different outcomes in antibody deficiency and immune dysregulation.
IVIG is administered directly into a vein, delivering purified pooled human IgG into the circulation. Its purpose depends on the clinical problem: treatment may replace deficient antibody function when immune protection is inadequate, or regulate abnormal immune activity when inflammation or autoimmunity is central. Thus, the route remains consistent while the therapeutic rationale differs.
IVIG is used when patients have primary or secondary antibody deficiencies that limit effective antibody function. In this setting, the preparation supplies pooled IgG antibodies that can support immune protection, including antibody-mediated responses relevant to infection. Its role is therefore replacement therapy, addressing inadequate host defense rather than primarily suppressing abnormal inflammation.
IVIG has applications beyond antibody replacement because its Fc-receptor interactions and complement effects can regulate abnormal immune activity. This makes it relevant to selected autoimmune and inflammatory disorders, where controlling immune signaling may be more important than supplying missing antibodies. Ongoing research examines how antibody composition, dose, and disease mechanism could support more targeted immune modulation.